Moral Emotions in Frontotemporal Dementia.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2019
Historique:
pubmed: 28 5 2019
medline: 20 9 2020
entrez: 26 5 2019
Statut: ppublish

Résumé

Emotions, with or without moral valence, appear to be altered in the behavioral variant of frontotemporal dementia (bvFTD) but the relative degree of moral emotion breakdown, which could be a marker of bvFTD diagnosis, remains unexplored. To assess moral emotions in bvFTD, to differentiate bvFTD from typical Alzheimer's disease (AD) based on moral emotion processing, and to provide a sensitive and specific assessment tool contributing to bvFTD diagnosis. We investigated moral emotions in 22 bvFTD patients, 15 patients with typical AD having positive CSF AD biomarkers, and 45 healthy controls. The 'Moral Emotions Assessment' task consisted in 42 scenarios exploring positive and negative moral emotions. To control for moral-specificity, we contrasted the 42 moral scenarios with 18 extra-moral scenarios eliciting the emotions without involving any inter-human moral context. bvFTD patients were more impaired in emotion processing than AD patients and healthy controls and had significantly poorer performance in the processing of moral emotions than of emotions without moral valence. ROC analyses of data on moral scenarios showed a high area under the curve (83%), and indicated a cut-off score (< 37/42) for differentiating bvFTD from AD with a sensitivity of 82% and specificity of 73%. Our findings demonstrate that bvFTD patients have disorders in emotion processing which is mainly related to failure regarding moral emotions. They also show that this deficit is reliably detected by the 'Moral Emotions Assessment' which represents a sensitive and specific diagnostic tool detecting bvFTD and differentiating it from AD.

Sections du résumé

BACKGROUND
Emotions, with or without moral valence, appear to be altered in the behavioral variant of frontotemporal dementia (bvFTD) but the relative degree of moral emotion breakdown, which could be a marker of bvFTD diagnosis, remains unexplored.
OBJECTIVE
To assess moral emotions in bvFTD, to differentiate bvFTD from typical Alzheimer's disease (AD) based on moral emotion processing, and to provide a sensitive and specific assessment tool contributing to bvFTD diagnosis.
METHODS
We investigated moral emotions in 22 bvFTD patients, 15 patients with typical AD having positive CSF AD biomarkers, and 45 healthy controls. The 'Moral Emotions Assessment' task consisted in 42 scenarios exploring positive and negative moral emotions. To control for moral-specificity, we contrasted the 42 moral scenarios with 18 extra-moral scenarios eliciting the emotions without involving any inter-human moral context.
RESULTS
bvFTD patients were more impaired in emotion processing than AD patients and healthy controls and had significantly poorer performance in the processing of moral emotions than of emotions without moral valence. ROC analyses of data on moral scenarios showed a high area under the curve (83%), and indicated a cut-off score (< 37/42) for differentiating bvFTD from AD with a sensitivity of 82% and specificity of 73%.
CONCLUSION
Our findings demonstrate that bvFTD patients have disorders in emotion processing which is mainly related to failure regarding moral emotions. They also show that this deficit is reliably detected by the 'Moral Emotions Assessment' which represents a sensitive and specific diagnostic tool detecting bvFTD and differentiating it from AD.

Identifiants

pubmed: 31127763
pii: JAD180991
doi: 10.3233/JAD-180991
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

887-896

Auteurs

Marc Teichmann (M)

Institut du Cerveau et de la Moelle épinière (ICM), FrontLab, Paris, France.
Département de Neurologie, Institut de la Mémoire et de la Maladie d'Alzheimer, Centre de Référence National 'FTD', Hôpital Pitié Salpêtrière, AP-HP, Paris, France.

Chloé Daigmorte (C)

Institut du Cerveau et de la Moelle épinière (ICM), FrontLab, Paris, France.

Aurélie Funkiewiez (A)

Institut du Cerveau et de la Moelle épinière (ICM), FrontLab, Paris, France.
Département de Neurologie, Institut de la Mémoire et de la Maladie d'Alzheimer, Centre de Référence National 'FTD', Hôpital Pitié Salpêtrière, AP-HP, Paris, France.

Clara Sanches (C)

Institut du Cerveau et de la Moelle épinière (ICM), FrontLab, Paris, France.

Maeva Camus (M)

Unité de Neuro-Psychiatrie Comportementale (IHU), Hôpital de la Pitié Salpêtrière, Paris, France.

Thomas Mauras (T)

Unité de Neuro-Psychiatrie Comportementale (IHU), Hôpital de la Pitié Salpêtrière, Paris, France.
Service de Psychiatrie, Hôpital Sainte-Anne, Paris, France.

Isabelle Le Ber (I)

Institut du Cerveau et de la Moelle épinière (ICM), FrontLab, Paris, France.
Département de Neurologie, Institut de la Mémoire et de la Maladie d'Alzheimer, Centre de Référence National 'FTD', Hôpital Pitié Salpêtrière, AP-HP, Paris, France.

Bruno Dubois (B)

Institut du Cerveau et de la Moelle épinière (ICM), FrontLab, Paris, France.
Département de Neurologie, Institut de la Mémoire et de la Maladie d'Alzheimer, Centre de Référence National 'FTD', Hôpital Pitié Salpêtrière, AP-HP, Paris, France.

Richard Levy (R)

Institut du Cerveau et de la Moelle épinière (ICM), FrontLab, Paris, France.
Département de Neurologie, Institut de la Mémoire et de la Maladie d'Alzheimer, Centre de Référence National 'FTD', Hôpital Pitié Salpêtrière, AP-HP, Paris, France.

Carole Azuar (C)

Institut du Cerveau et de la Moelle épinière (ICM), FrontLab, Paris, France.
Département de Neurologie, Institut de la Mémoire et de la Maladie d'Alzheimer, Centre de Référence National 'FTD', Hôpital Pitié Salpêtrière, AP-HP, Paris, France.
Unité de Neuro-Psychiatrie Comportementale (IHU), Hôpital de la Pitié Salpêtrière, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH